SK284331B6 - Liečivo na liečenie amyotrofickej laterálnej sklerózy - Google Patents

Liečivo na liečenie amyotrofickej laterálnej sklerózy Download PDF

Info

Publication number
SK284331B6
SK284331B6 SK1806-98A SK180698A SK284331B6 SK 284331 B6 SK284331 B6 SK 284331B6 SK 180698 A SK180698 A SK 180698A SK 284331 B6 SK284331 B6 SK 284331B6
Authority
SK
Slovakia
Prior art keywords
topiramate
formula
lateral sclerosis
amyotrophic lateral
als
Prior art date
Application number
SK1806-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK180698A3 (en
Inventor
Richard P. Shank
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of SK180698A3 publication Critical patent/SK180698A3/sk
Publication of SK284331B6 publication Critical patent/SK284331B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1806-98A 1996-06-28 1997-06-24 Liečivo na liečenie amyotrofickej laterálnej sklerózy SK284331B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2200696P 1996-06-28 1996-06-28
PCT/US1997/010955 WO1998000131A1 (en) 1996-06-28 1997-06-24 Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (als)

Publications (2)

Publication Number Publication Date
SK180698A3 SK180698A3 (en) 2000-07-11
SK284331B6 true SK284331B6 (sk) 2005-01-03

Family

ID=21807346

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1806-98A SK284331B6 (sk) 1996-06-28 1997-06-24 Liečivo na liečenie amyotrofickej laterálnej sklerózy

Country Status (22)

Country Link
US (1) US5753694A (uk)
EP (1) EP0936908B1 (uk)
JP (1) JP2000514426A (uk)
AP (1) AP1167A (uk)
AT (1) ATE214274T1 (uk)
AU (1) AU725093B2 (uk)
BR (1) BR9710993A (uk)
CA (1) CA2258892C (uk)
CZ (1) CZ293945B6 (uk)
DE (1) DE69711067T2 (uk)
DK (1) DK0936908T3 (uk)
ES (1) ES2176755T3 (uk)
HU (1) HUP9904318A3 (uk)
IL (1) IL127717A (uk)
NO (1) NO317136B1 (uk)
NZ (1) NZ333588A (uk)
PT (1) PT936908E (uk)
SI (1) SI0936908T1 (uk)
SK (1) SK284331B6 (uk)
UA (1) UA46112C2 (uk)
WO (1) WO1998000131A1 (uk)
ZA (1) ZA975764B (uk)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
WO2000061138A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
WO2000076493A1 (en) 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
EP1345602B1 (en) * 2000-11-30 2010-07-21 Novodermix International Limited Wound healing
DE60219961T8 (de) * 2001-02-02 2008-04-17 Ortho-Mcneil Pharmaceutical, Inc. Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
MXPA04004572A (es) * 2001-11-14 2005-07-05 Ralph Ryback Metodo para el tratamiento de enfermedades autoinmunes.
AU2003218345A1 (en) * 2002-11-06 2004-06-03 Mount Sinai School Of Medicine Treatment of amyotrophic lateral sclerosis with nimesulide
US20060041022A1 (en) * 2002-11-06 2006-02-23 Pasinetti Giulio M Treatment of amyotrophic lateral sclerosis with nimesulide
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
DE602005008084D1 (de) * 2004-08-24 2008-08-21 Janssen Pharmaceutica Nv Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
IS7748A (is) * 2005-03-17 2006-09-18 Actavis Group Samsetning fyrir töflur sem innihalda topiramate
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
FR2903019A1 (fr) * 2006-06-30 2008-01-04 Univ Claude Bernard Lyon I Eta Utilisation d'un inhibiteur de l'anhydrase carbonique, pour la preparation d'un medicament destine a traiter des degenerescences du muscle squelettique
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates

Also Published As

Publication number Publication date
US5753694A (en) 1998-05-19
HUP9904318A2 (hu) 2000-05-28
DE69711067T2 (de) 2002-09-19
NZ333588A (en) 2000-07-28
UA46112C2 (uk) 2002-05-15
JP2000514426A (ja) 2000-10-31
AU3501097A (en) 1998-01-21
NO317136B1 (no) 2004-08-23
ES2176755T3 (es) 2002-12-01
CA2258892C (en) 2005-08-09
NO986054L (no) 1999-03-01
AP1167A (en) 2003-06-30
EP0936908B1 (en) 2002-03-13
BR9710993A (pt) 2002-02-26
ATE214274T1 (de) 2002-03-15
WO1998000131A1 (en) 1998-01-08
DE69711067D1 (de) 2002-04-18
SK180698A3 (en) 2000-07-11
PT936908E (pt) 2002-08-30
HUP9904318A3 (en) 2001-02-28
AP9801428A0 (en) 1998-12-31
CZ293945B6 (cs) 2004-08-18
CA2258892A1 (en) 1998-01-08
SI0936908T1 (en) 2002-12-31
ZA975764B (en) 1998-12-28
EP0936908A1 (en) 1999-08-25
DK0936908T3 (da) 2002-05-27
IL127717A0 (en) 1999-10-28
AU725093B2 (en) 2000-10-05
IL127717A (en) 2004-09-27
CZ427998A3 (cs) 1999-08-11
NO986054D0 (no) 1998-12-22

Similar Documents

Publication Publication Date Title
SK284331B6 (sk) Liečivo na liečenie amyotrofickej laterálnej sklerózy
SK180598A3 (en) Anticonvulsant sulfamate derivatives useful in treating obesity
US6620819B2 (en) Anticonvulsant derivatives useful in treating psychosis
de Vallière et al. A novel OGR1 (GPR68) inhibitor attenuates inflammation in murine models of colitis
HUP0302307A2 (hu) Görcsellenes aktivitású származékok a II. típusú diabétesz mellitusz és az X-szindróma megelőzésére
SK180498A3 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
US20210069135A1 (en) Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
US11213517B2 (en) Pharmaceutical combination comprising a T-type calcium channel blocker
US5760006A (en) Anticonvulsant derivatives useful in treating psoriasis
US9205135B2 (en) Podocyte pH modulation and uses thereof
US6486198B1 (en) Compounds and methods for the treatment of post traumatic stress disorder
CA2267945C (en) Anticonvulsant derivatives useful in treating neuropathic pain
KR100496933B1 (ko) 근위축성외측경화증치료에유용한항경련성유도체
SK180398A3 (en) Anticonvulsant derivatives useful in treating psoriasis
JP2002543123A (ja) コカイン依存症の処置において有用な抗痙攣性誘導体
Philipp et al. A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis
KR20000022252A (ko) 건선치료에 유용한 항경련성 유도체
CN1223578A (zh) 用于治疗肌萎缩性侧索硬化(als)的抗惊厥药衍生物
Roof Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo